A recent article published in the January 2014 edition of Obstetrics and Gynecology titled “Robotic compared with laparoscopic sacrocolpopexy: a randomized controlled trial.” lives up to its title and compares the safety and efficacy of robot-assisted to traditional sacrocolpoplexy.

The team, led by JT Anger, writes “Laparoscopic and robotic sacrocolpopexy are widely used for pelvic organ prolapse (POP) treatment” but that “Evidence comparing outcomes and costs is lacking.”  Accordingly, this study made just that comparison.   The patients studied were female, and totalled 78 – thirty-eight traditional surgeries and forty robot-assisted surgeries.

In general, this small study found the procedures to be fairly comparable, but it was found that robot-assisted surgery resulted in longer operating time and patients suffering from higher pain scores one week after surgery.  Further, the cost of robotic surgery was significantly higher than  the traditional laparoscopic procedure.

While the safety and efficacy of robotic surgery is ever increasing, it is important for patients to be fully aware of risk and complication rates associated with this still-novel procedure.  Due to the fact that Da Vinci, the manufacturer of many popular surgical robot systems, has failed time and again to adequately warn users of the risks associated with robotic surgery, a number of Da Vinci Surgical Robot lawsuits have been filed.

If you or a loved one underwent a robotically-assisted surgery and suffered complications or unintended side-effects, you too may be entitled to significant financial compensation from the manufacturer of the device used.  For a free, no-obligation case consultation, contact our team of Da Vinci surgical robots lawyers at the information provided below.  We have the experience, resources, and skills required to win the justice you deserve.  Call today and see how we can help.

(855) 452 – 5529

justinian@dangerousdrugs.us